Fitness Trackers Helpful For Cancer Assessments

NOURAN AMIN | July 25, 2018

article image
A new study published in the journal Digital Medicine found that fitness trackers can be used as a valuable tool to only assess the quality of life but the daily functioning of cancer patients during the course of their treatment. The trackers, also called wearable activity monitors, include commercial wrist devices that record the wearer's step counts, stairs climbed, calories, heart rate and sleep. "One of the challenges in treating patients with advanced cancer is obtaining ongoing, timely, objective data about their physical status during therapy," explains Andrew Hendifar, MD, the medical director for pancreatic cancer at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute. "After all, patients typically spend most of their time at home or work, not in a clinic, and their health statuses change from day today."Hendifar served as the principal investigator of the study and Gillian Gresham, Ph.D., served as the postdoctoral scientist at the cancer institute and first author for the study.

Spotlight

Anthelio Healthcare Solutions

Anthelio is now Atos. Anthelio is the largest independent provider of healthcare technology solutions in the market. We offer solutions across the spectrum of care, providing customers the ability to solve their critical technology needs from a single source while delivering cost savings and efficiencies. Our end-to-end solutions include IT infrastructure services, IT applications management, EHR optimization, Patient Engagement, Analytics, and Revenue Cycle Management (RCM) including HIM Services, Patient Financial Services and Cancer Registry Services. Anthelio drives sustainable value to over 63,000 physicians and nurses in hundreds of healthcare organizations supporting their annual revenue of over $67 billion and impacting quality care to over 60 million patients.

OTHER ARTICLES

Comparing HydroxyChloroquine Trials

Article | April 1, 2020

One minor side effect of the pandemic is that perhaps more people will learn about what drug research and clinical trials can really be like. Today’s example: we have a clinical trial of hydroxychloroquine from Wuhan that has just published on a preprint server. What’s good is that this one is blinded, randomized, and controlled (like the earlier hydroxychloroquine which one I blogged about here from Zhejiang University, so we can actually talk about it rather than just spend all our time wondering what the heck is going on.

Read More

Advance Your Pharma Supply Chain Planning during a Pandemic

Article | April 1, 2020

One predominant and common element within our pharmaceutical industry, is our devotions to patients. Within supply chain there is always a focus on ensuring the right product is delivered to the right place at the right time in order to ensure patient safety and the continuity of medicinal supplies. With the spread of COVID-19 across 117 countries and counting, every supply chain needs to evaluate their global footprint and develop contingency plans within their end to end operations.

Read More

As Pandemic Continues, Rafael Pharmaceuticals Enrolls Patients in Phase III Pancreatic Cancer Trial

Article | April 1, 2020

That simple truth about the severity of the disease is one of the reasons that Rafael Pharmaceuticals is slowly continuing with a Phase III trial in metastatic pancreatic cancer during the COVID-19 pandemic. While many companies have paused enrollment in clinical trials during the outbreak, Cranbury, N.J,-based Rafael opted to continue to enroll patients in its Phase III AVENGER 500 study of its lead compound CPI-613 (devimistat) in combination with modified Folfirinox (mFFX) as first-line therapy for the disease. Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have. After discussing the matter of the trial with the company’s leadership team, Luther said they felt comfortable leaving the decision of whether or not the trial should continue to the conducting institute.

Read More

Decentralized Clinical Trials: Imperative for Pharma Sector to fight COVID19

Article | April 1, 2020

These are unprecedented times. The world is mobbed by a contagion virus, putting people’s health at risk, threatening to destabilize economies. It has already put global healthcare systems under tremendous pressures, and managed to resist efforts to contain it. Even though coronaviruses are not new, this COVID-19 strain has created panic and forced us to be locked down in our homes sans any movement for weeks, if not months. Organizations are fighting an intense battle to keep their workforce safe, minimize risk, and ensure business continuity. For the Life Sciences industry, however, the challenge is even more significant. The whole world is looking at them to come up with a vaccine and a cure. But that is easier said than done. Bringing a new drug to market is an uphill battle and requires rigorous clinical trials. This process already has regulatory challenges. With the current lockdown situation, the Pharma community is grappled with the challenge of continuing some of the critical and time-sensitive in-flight trials so that their regulatory submission, registration, and market entry are not impacted. But all may not be lost. With the right technology solution, it is possible to turn the situation around rapidly.

Read More

Spotlight

Anthelio Healthcare Solutions

Anthelio is now Atos. Anthelio is the largest independent provider of healthcare technology solutions in the market. We offer solutions across the spectrum of care, providing customers the ability to solve their critical technology needs from a single source while delivering cost savings and efficiencies. Our end-to-end solutions include IT infrastructure services, IT applications management, EHR optimization, Patient Engagement, Analytics, and Revenue Cycle Management (RCM) including HIM Services, Patient Financial Services and Cancer Registry Services. Anthelio drives sustainable value to over 63,000 physicians and nurses in hundreds of healthcare organizations supporting their annual revenue of over $67 billion and impacting quality care to over 60 million patients.

Events